Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Jordyn H Feingold, Douglas A Drossman
Stigma, defined as social devaluation based on negative stereotypes toward a particular population, is prevalent within health care and is a common phenomenon in disorders of gut-brain interaction (DGBI). Characteristically, DGBI including functional dyspepsia (FD) lack a structural etiology to explain symptoms, have high psychiatric co-morbidity, and respond to neuromodulators traditionally used to treat psychopathology. As a result, these disorders are frequently and wrongly presumed to be psychiatric and carry a great deal of stigma...
February 2021: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#22
REVIEW
Christopher J Black, Douglas A Drossman, Nicholas J Talley, Johannah Ruddy, Alexander C Ford
Gastrointestinal symptoms are highly prevalent, but many people who have them will have no organic explanation for their symptoms. Most of these people will be labelled as having a functional gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or functional constipation. These conditions affect up to 40% of people at any one point in time, and two-thirds of these people will have chronic, fluctuating symptoms. The pathophysiology of functional gastrointestinal disorders is complex, but involves bidirectional dysregulation of gut-brain interaction (via the gut-brain axis), as well as microbial dysbiosis within the gut, altered mucosal immune function, visceral hypersensitivity, and abnormal gastrointestinal motility...
November 21, 2020: Lancet
#23
JOURNAL ARTICLE
Jordyn H Feingold, Douglas A Drossman, William Chey, Jacob E Kurlander, Carolyn B Morris, Shrikant Bangdiwala, Laurie Keefer
BACKGROUND: An effective patient-physician relationship (PPR) is essential to the care of patients with irritable bowel syndrome (IBS). After developing a PPR questionnaire for patients, we sought to develop and validate an IBS-specific instrument to measure physician expectations of the PPR. METHODS: We conducted focus groups about PPRs among 15 clinicians who treat patients with IBS from community and academic centers. Qualitative analysis was used to generate the Patient-Physician Relationship Scale -Physician RESULTS: The PPRS-Physician contained 35 questions pertaining to interpersonal and psychosocial features considered desirable or undesirable in a relationship with IBS patients...
February 2021: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
#24
JOURNAL ARTICLE
Ami D Sperber, Shrikant I Bangdiwala, Douglas A Drossman, Uday C Ghoshal, Magnus Simren, Jan Tack, William E Whitehead, Dan L Dumitrascu, Xuicai Fang, Shin Fukudo, John Kellow, Edith Okeke, Eamonn M M Quigley, Max Schmulson, Peter Whorwell, Timothy Archampong, Payman Adibi, Viola Andresen, Marc A Benninga, Bruno Bonaz, Serhat Bor, Luis Bustos Fernandez, Suck Chei Choi, Enrico S Corazziari, Carlos Francisconi, Albis Hani, Leonid Lazebnik, Yeong Yeh Lee, Agata Mulak, M Masudur Rahman, Javier Santos, Mashiko Setshedi, Ari Fahrial Syam, Stephen Vanner, Reuben K Wong, Aurelio Lopez-Colombo, Valeria Costa, Ram Dickman, Motoyori Kanazawa, Ammar Hassanzadeh Keshteli, Rutaba Khatun, Iradj Maleki, Pierre Poitras, Nitesh Pratap, Oksana Stefanyuk, Sandie Thomson, Judith Zeevenhooven, Olafur S Palsson
BACKGROUND & AIMS: Although functional gastrointestinal disorders (FGIDs), now called disorders of gut-brain interaction, have major economic effects on health care systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. METHODS: Data were collected via the Internet in 24 countries, personal interviews in 7 countries, and both in 2 countries, using the Rome IV diagnostic questionnaire, Rome III irritable bowel syndrome questions, and 80 items to identify variables associated with FGIDs...
January 2021: Gastroenterology
#25
REVIEW
Antonina Mikocka-Walus, Alexander C Ford, Douglas A Drossman
Gut-brain dysregulation has been recognized by the scientific community as being crucial to the understanding of chronic gastrointestinal conditions, and this has translated into the practice of a newly established discipline, psychogastroenterology. Along with psychotherapy, antidepressants (a subtype of central neuromodulators) have been proposed as treatments for gut-brain disorders that might benefit both psychological and gastrointestinal health. Antidepressants have been found to be effective for the treatment of comorbid anxiety and depression, pain and impaired sleep...
March 2020: Nature Reviews. Gastroenterology & Hepatology
#26
REVIEW
Douglas A Drossman, Johannah Ruddy
Changes in our health care system have posed challenges for the patient-provider relationship (PPR) and may have negative consequences. For the clinician, due to lower reimbursements from third party payers, and increased administrative tasks such as the electronic medical record (EMR) and certification requirements, clinic visit time is now one fifth that of decades ago. Clinicians may order diagnostic studies and imaging as a substitute for face to face time as it is seen to save time and increase relative value units (RVUs)...
December 13, 2019: Clinical Gastroenterology and Hepatology
#27
REVIEW
Helen B Murray, Adrienne S Juarascio, Carlo Di Lorenzo, Douglas A Drossman, Jennifer J Thomas
Rumination syndrome (RS) is characterized by the repeated regurgitation of material during or soon after eating with the subsequent rechewing, reswallowing, or spitting out of the regurgitated material. Rumination syndrome is classified as both a "Functional Gastroduodenal Disorder" (by the Rome Foundation's Functional Gastrointestinal Disorders: Disorders of Gut-Brain Interaction, 4th edition) and a "Feeding and Eating Disorder" (by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition). Rumination syndrome is a disorder that is often inaccurately diagnosed or missed, resulting in patients experiencing protracted symptoms and not receiving treatment for long periods...
April 2019: American Journal of Gastroenterology
#28
EDITORIAL
Douglas A Drossman
No abstract text is available yet for this article.
November 9, 2018: Gastroenterology
#29
EDITORIAL
Douglas A Drossman
No abstract text is available yet for this article.
November 9, 2018: Gastroenterology
#30
REVIEW
Hans Törnblom, Douglas A Drossman
PURPOSE OF REVIEW: The functional gastrointestinal disorders, or disorders of gut-brain interaction as defined by the Rome IV criteria, are the most common diagnostic entities in gastroenterology. Treatments that address the dysregulation of gut-brain interaction with these disorders are increasingly gaining interest as a better option than for example traditional analgesics, particularly opioids. Antidepressants, antianxiety and antipsychotic medications, and visceral analgesics, now termed neuromodulators, are included in this update addressing the evidence of treatment benefit in disorders of brain-gut interaction...
November 5, 2018: Current Gastroenterology Reports
#31
REVIEW
Douglas A Drossman, Jan Tack, Alexander C Ford, Eva Szigethy, Hans Törnblom, Lukas Van Oudenhove
BACKGROUND & AIMS: Central neuromodulators (antidepressants, antipsychotics, and other central nervous system-targeted medications) are increasingly used for treatment of functional gastrointestinal disorders (FGIDs), now recognized as disorders of gut-brain interaction. However, the available evidence and guidance for the use of central neuromodulators in these conditions is scanty and incomplete. In this Rome Foundation Working Team report, a multidisciplinary team summarized available research evidence and clinical experience to provide guidance and treatment recommendations...
March 2018: Gastroenterology
#32
JOURNAL ARTICLE
Douglas A Drossman
No abstract text is available yet for this article.
November 2017: Gastroenterology & Hepatology
#33
REVIEW
Eva Szigethy, Mitchell Knisely, Douglas Drossman
Opioids were one of the earliest classes of medications used for pain across a variety of conditions, but morbidity and mortality have been increasingly associated with their chronic use. Despite these negative consequences, chronic opioid use is increasing worldwide, with the USA and Canada having the highest rates. Chronic opioid use for noncancer pain can have particularly negative effects in the gastrointestinal and central nervous systems, including opioid-induced constipation, narcotic bowel syndrome, worsening psychopathology and addiction...
March 2018: Nature Reviews. Gastroenterology & Hepatology
#34
JOURNAL ARTICLE
Egilius L H Spierings, Douglas A Drossman, Byron Cryer, M Mazen Jamal, Taryn Losch-Beridon, Shadreck M Mareya, Martin Wang
Objective: The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore the effects of methadone on treatment response. Methods: In the primary study, adults with OIC (fewer than three spontaneous bowel movements [SBMs] per week) were randomized to receive lubiprostone 24 mcg or placebo twice daily for 12 weeks...
June 1, 2018: Pain Medicine
#35
JOURNAL ARTICLE
Robyn Lewis Claar, Miranda A L van Tilburg, Bisher Abdullah, Shelby Langer, Dalia Sherif, William E Whitehead, Douglas A Drossman, Rona L Levy
OBJECTIVES: For patients with Crohn disease (CD), symptom reporting may not coincide with disease state; patients in remission may continue to report symptoms and pain, whereas other patients may be symptom-free despite a flare. This phenomenon has been documented in adults but only recently assessed in pediatric patients. The present study assessed the role of pain reporting and disease state in pediatric patients with CD in understanding psychological distress and quality of life. METHODS: Participants included 116 children and adolescents ages 8 to 18 years with CD who completed self-report questionnaires assessing pain, disease symptoms, depression, anxiety, functional disability, and quality of life...
October 2017: Journal of Pediatric Gastroenterology and Nutrition
#36
JOURNAL ARTICLE
Leticia Delgado-Herrera, Kathryn Lasch, Bernhardt Zeiher, Anthony J Lembo, Douglas A Drossman, Benjamin Banderas, Kathleen Rosa, Christopher Lademacher, Rob Arbuckle
BACKGROUND: To evaluate the psychometric properties of the newly developed seven-item Irritable Bowel Syndrome - Diarrhea predominant (IBS-D) Daily Symptom Diary and four-item Event Log using phase II clinical trial safety and efficacy data in patients with IBS-D. This instrument measures diarrhea (stool frequency and stool consistency), abdominal pain related to IBS-D (stomach pain, abdominal pain, abdominal cramps), immediate need to have a bowel movement (immediate need and accident occurrence), bloating, pressure, gas, and incomplete evacuation...
September 2017: Therapeutic Advances in Gastroenterology
#37
JOURNAL ARTICLE
Peter B Cotton, Qi Pauls, Jamila Keith, Andre Thornhill, Douglas Drossman, April Williams, Valerie Durkalski-Mauldin
BACKGROUND AND AIMS: The EPISOD (Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction) study randomized patients with post-cholecystectomy pain, and little or no objective evidence for biliary obstruction, to sphincterotomy or sham intervention. Results at 1 year showed no benefit for the active treatment. We now report the outcomes at up to 5 years. METHODS: One hundred three patients completing 1 year, and still blinded to treatment allocation, were enrolled and followed by phone every 6 months for a median of 58 months (range, 17-71 months)...
January 2018: Gastrointestinal Endoscopy
#38
JOURNAL ARTICLE
Douglas A Drossman
No abstract text is available yet for this article.
September 2016: Lancet. Gastroenterology & Hepatology
#39
REVIEW
W Harley Sobin, Thomas W Heinrich, Douglas A Drossman
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they work, the differences between classes and individual agents, and the various adverse effects are outlined...
May 2017: American Journal of Gastroenterology
#40
REVIEW
Max J Schmulson, Douglas A Drossman
Functional gastrointestinal disorders (FGIDs) are diagnosed and classified using the Rome criteria; the criteria may change over time as new scientific data emerge. The Rome IV was released in May 2016. The aim is to review the main changes in Rome IV. FGIDs are now called disorders of gut-brain interaction ( DGBI ). Rome IV has a multicultural rather than a Western-culture focus. There are new chapters including multicultural, age-gender-women's health, intestinal microenvironment, biopsychosocial, and centrally mediated disorders...
April 30, 2017: Journal of Neurogastroenterology and Motility
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
